2,5-dihydroxymethyl-3,6-dimethylpyrazine

Known as: liguzinediol 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
012320122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Liguzinediol (2,5-dihydroxymethyl-3,6-dimethylpyrazine, LZDO) is a potential agent for the low-risk treatment of heart failure. 2… (More)
Is this relevant?
2017
2017
It has been demonstrated that liguzinediol (2,5-dihydroxymethyl-3,6-dimethylpyrazine, LZDO), a derivative of ligustrazine from… (More)
Is this relevant?
2016
2016
Cardiac fibrosis plays a causal role in the development of heart failure, and anti-fibrotic therapy represents a promising… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
2016
2016
2,5-Dihydroxymethyl-3,6-dimethylpyrazine (liguzinediol) has been recently discovered as a potential agent for treatment of heart… (More)
Is this relevant?
2014
2014
Aim:Liguzinediol is a novel derivative of ligustrazine isolated from the traditional Chinese medicine Chuanxiong (Ligusticum… (More)
Is this relevant?
2014
2014
The potent positive inotropic effect, together with the relatively low safety risk of liguzinediol (LZDO), relative to currently… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
Liguzinediol (LZDO) ester prodrugs 3-5 were synthesized and evaluated in vitro and in vivo for their potential use in prolonging… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2013
2013
Liguzinediol (LZDO) could mediate the positive inotropic effects through sarcoplasmic reticulum Ca2+ ATPase-dependent mechanism… (More)
Is this relevant?
2012
2012
AIMS The present work investigated the underlying mechanism for the positive inotropic effect of liguzinediol (LZDO) in isolated… (More)
Is this relevant?
2012
2012
Ultra performance liquid chromatography/quadrupole-time-of-flight mass spectrometry (UPLC/QTOF MS) was employed to investigate… (More)
  • figure 2
  • figure 1
  • table 1
Is this relevant?